<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T00:37:51Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2072/474736" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2072/474736</identifier><datestamp>2025-05-08T15:22:38Z</datestamp><setSpec>com_2072_98</setSpec><setSpec>col_2072_378192</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:Item id="hdl_2072_474736">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:2072/474736</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Adipokines as New Biomarkers of Immune Recovery : Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy</dc:title>
               <dc:creator>Yeregui, Elena</dc:creator>
               <dc:creator>Masip, Jenifer</dc:creator>
               <dc:creator>Viladés, Consuelo</dc:creator>
               <dc:creator>Domingo, Pere</dc:creator>
               <dc:creator>Pacheco, Yolanda M</dc:creator>
               <dc:creator>Blanco, Julià</dc:creator>
               <dc:creator>Mallolas Masferrer, Josep</dc:creator>
               <dc:creator>Alba, Verónica</dc:creator>
               <dc:creator>Vargas, Montserrat</dc:creator>
               <dc:creator>García-Pardo, Graciano</dc:creator>
               <dc:creator>Negredo Puigmal, Eugènia</dc:creator>
               <dc:creator>Olona, Montserrat</dc:creator>
               <dc:creator>Vidal-González, Judit</dc:creator>
               <dc:creator>Peraire, Maria</dc:creator>
               <dc:creator>Martí, Anna</dc:creator>
               <dc:creator>Reverté Calvet, Laia</dc:creator>
               <dc:creator>Gómez-Bertomeu, Fréderic</dc:creator>
               <dc:creator>Leal, Manuel</dc:creator>
               <dc:creator>Vidal, Francesc</dc:creator>
               <dc:creator>Peraire, Joaquim</dc:creator>
               <dc:creator>Rull, Anna</dc:creator>
               <dc:creator>Universitat Autònoma de Barcelona</dc:creator>
               <dc:subject>Adipokines</dc:subject>
               <dc:subject>Antiretroviral therapy</dc:subject>
               <dc:subject>HIV</dc:subject>
               <dc:subject>Immunodiscordant response</dc:subject>
               <dc:subject>Poor immune recovery</dc:subject>
               <dc:description>A significant proportion of people living with HIV (PLHIV) who successfully achieve virological suppression fail to recover CD4 T-cell counts. Since adipose tissue has been discovered as a key immune organ, this study aimed to assess the role of adipokines in the HIV immunodiscordant response. This is a multicenter prospective study including 221 PLHIV starting the first antiretroviral therapy (ART) and classified according to baseline CD4 T-cell counts/µL (controls > 200 cells/µL and cases ≤ 200 cells/µL). Immune failure recovery was considered when cases did not reach more than 250 CD4 T cells/µL at 144 weeks (immunological nonresponders, INR). Circulating adipokine concentrations were longitudinally measured using enzyme-linked immunosorbent assays. At baseline, apelin receptor (APLNR) and zinc-alpha-2-glycoprotein (ZAG) concentrations were significantly lower in INRs than in immunological responders (p = 0.043 and p = 0.034), and they remained lower during all ART follow-up visits (p = 0.044 and p = 0.028 for APLNR, p = 0.038 and p = 0.010 for ZAG, at 48 and 144 weeks, respectively). ZAG levels positively correlated with retinol-binding protein 4 (RBP4) levels (p &lt; 0.01), and low circulating RBP4 concentrations were related to a low CD4 T-cell gain (p = 0.018 and p = 0.039 at 48 and 144 weeks, respectively). Multiple regression adjusted for clinical variables and adipokine concentrations confirmed both low APLNR and RBP4 as independent predictors for CD4 T cells at 144 weeks (p &lt; 0.001). In conclusion, low APLNR and RBP4 concentrations were associated with poor immune recovery in treated PLHIV and could be considered predictive biomarkers of a discordant immunological response.</dc:description>
               <dc:date>2022</dc:date>
               <dc:type>Article</dc:type>
               <dc:relation>Ministerio de Economía y Competitividad PI16/00503</dc:relation>
               <dc:relation>Ministerio de Economía y Competitividad RD12/0017/0005</dc:relation>
               <dc:relation>Ministerio de Economía y Competitividad RD16/0025/0006</dc:relation>
               <dc:relation>Instituto de Salud Carlos III PI18/01216</dc:relation>
               <dc:relation>Instituto de Salud Carlos III PI19/01337</dc:relation>
               <dc:relation>Instituto de Salud Carlos III PI20/00326</dc:relation>
               <dc:relation>International journal of molecular sciences ; Vol. 23 Núm. 4 (2-2 2022), p. 2202</dc:relation>
               <dc:rights>open access</dc:rights>
               <dc:rights>Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.</dc:rights>
               <dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
               <dc:publisher/>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>